Hepatic Expression of Mature Transforming Growth Factor Beta 1 in Transgenic Mice Results in Multiple Tissue Lesions

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1995 Mar 28

PMID 7708687

Citations 198

Authors

N Sanderson

V Factor

P Nagy

J Kopp

P Kondaiah

L Wakefield

A B Roberts

M B Sporn

S S Thorgeirsson

Affiliations

Soon will be listed here.

Abstract

Aberrant expression of transforming growth factor beta 1 (TGF-beta 1) has been implicated in a number of disease processes, particularly those involving fibrotic and inflammatory lesions. To determine the in vivo effects of overexpression of TGF-beta 1 on the function and structure of hepatic as well as extrahepatic tissues, transgenic mice were generated containing a fusion gene (Alb/TGF-beta 1) consisting of modified porcine TGF-beta 1 cDNA under the control of the regulatory elements of the mouse albumin gene. Five transgenic lines were developed, all of which expressed the Alb/TGF-beta 1 transgene selectively in hepatocytes. The transgenic line 25 expressing the highest level of the transgene in the liver also had high (> 10-fold over control) plasma levels of TGF-beta 1. Hepatic fibrosis and apoptotic death of hepatocytes developed in all the transgenic lines but was more pronounced in line 25. The fibrotic process was characterized by deposition of collagen around individual hepatocytes and within the space of Disse in a radiating linear pattern. Several extrahepatic lesions developed in line 25, including glomerulonephritis and renal failure, arteritis and myocarditis, as well as atrophic changes in pancreas and testis. The results from this transgenic model strongly support the proposed etiological role for TGF-beta 1 in a variety of fibrotic and inflammatory disorders. The transgenic model may also provide an appropriate paradigm for testing therapeutic interventions aimed at neutralizing the detrimental effects of this important cytokine.

Citing Articles

Mitogen-Activated Protein Kinase Phosphatase-5 is Required for TGF-β Signaling Through a JNK-Dependent Pathway.

Dorry S, Perla S, Bennett A Mol Cell Biol. 2024; 45(1):17-31.

PMID: 39607740 PMC: 11693473. DOI: 10.1080/10985549.2024.2426665.

Resveratrol treatment ameliorates hepatic damage via the TGF-β/SMAD signaling pathway in a phenobarbital/CCl-induced hepatic fibrosis model.

Aykac M, Balkan E, Gedi Kli S, Ozturk N Iran J Basic Med Sci. 2024; 27(9):1124-1133.

PMID: 39055873 PMC: 11266736. DOI: 10.22038/IJBMS.2024.75737.16398.

MAPK Phosphatase-5 is required for TGF-β signaling through a JNK-dependent pathway.

Dorry S, Perla S, Bennett A bioRxiv. 2024; .

PMID: 38979264 PMC: 11230413. DOI: 10.1101/2024.06.27.600976.

Pleiotropic Action of TGF-Beta in Physiological and Pathological Liver Conditions.

Braczkowski M, Kufel K, Kulinska J, Czyz D, Dittmann A, Wiertelak M Biomedicines. 2024; 12(4).

PMID: 38672279 PMC: 11048627. DOI: 10.3390/biomedicines12040925.

TGF-β signaling in health, disease, and therapeutics.

Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C Signal Transduct Target Ther. 2024; 9(1):61.

PMID: 38514615 PMC: 10958066. DOI: 10.1038/s41392-024-01764-w.

References

Aviv H, Leder P . Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci U S A. 1972; 69(6):1408-12. PMC: 426713. DOI: 10.1073/pnas.69.6.1408. View

Border W, Noble N . Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994; 331(19):1286-92. DOI: 10.1056/NEJM199411103311907. View

Assoian R, Komoriya A, Meyers C, Miller D, Sporn M . Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983; 258(11):7155-60. View

Low M, Hammer R, Goodman R, Habener J, Palmiter R, Brinster R . Tissue-specific posttranslational processing of pre-prosomatostatin encoded by a metallothionein-somatostatin fusion gene in transgenic mice. Cell. 1985; 41(1):211-9. DOI: 10.1016/0092-8674(85)90075-3. View

Desmet V . Alcoholic liver disease. Histological features and evolution. Acta Med Scand Suppl. 1985; 703:111-26. DOI: 10.1111/j.0954-6820.1985.tb08909.x. View

Pinkert C, Ornitz D, Brinster R, Palmiter R . An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice. Genes Dev. 1987; 1(3):268-76. DOI: 10.1101/gad.1.3.268. View

Flanders K, Thompson N, Cissel D, Van Obberghen-Schilling E, Baker C, Kass M . Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes. J Cell Biol. 1989; 108(2):653-60. PMC: 2115454. DOI: 10.1083/jcb.108.2.653. View

Czaja M, Weiner F, Flanders K, Giambrone M, Wind R, BIEMPICA L . In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol. 1989; 108(6):2477-82. PMC: 2115595. DOI: 10.1083/jcb.108.6.2477. View

Brunner A, Marquardt H, Malacko A, Lioubin M, Purchio A . Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor beta 1 precursor. Expression and characterization of mutant proteins. J Biol Chem. 1989; 264(23):13660-4. View

10.

Lyons R, Moses H . Transforming growth factors and the regulation of cell proliferation. Eur J Biochem. 1990; 187(3):467-73. DOI: 10.1111/j.1432-1033.1990.tb15327.x. View

11.

Anscher M, Crocker I, Jirtle R . Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res. 1990; 122(1):77-85. View

12.

Lyons R, Gentry L, Purchio A, Moses H . Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol. 1990; 110(4):1361-7. PMC: 2116088. DOI: 10.1083/jcb.110.4.1361. View

13.

Nakatsukasa H, Nagy P, Evarts R, Hsia C, Marsden E, Thorgeirsson S . Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest. 1990; 85(6):1833-43. PMC: 296648. DOI: 10.1172/JCI114643. View

14.

Okuda S, Languino L, Ruoslahti E, Border W . Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. J Clin Invest. 1990; 86(2):453-62. PMC: 296747. DOI: 10.1172/JCI114731. View

15.

Moses H, Yang E, Pietenpol J . TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell. 1990; 63(2):245-7. DOI: 10.1016/0092-8674(90)90155-8. View

16.

Massague J . The transforming growth factor-beta family. Annu Rev Cell Biol. 1990; 6:597-641. DOI: 10.1146/annurev.cb.06.110190.003121. View

17.

Castilla A, Prieto J, Fausto N . Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med. 1991; 324(14):933-40. DOI: 10.1056/NEJM199104043241401. View

18.

Lin H, Wang X, Weinberg R, Lodish H . Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell. 1992; 68(4):775-85. DOI: 10.1016/0092-8674(92)90152-3. View

19.

Evarts R, Nakatsukasa H, Marsden E, Hu Z, Thorgeirsson S . Expression of transforming growth factor-alpha in regenerating liver and during hepatic differentiation. Mol Carcinog. 1992; 5(1):25-31. DOI: 10.1002/mc.2940050107. View

20.

Samuel S, Hurta R, Kondaiah P, Khalil N, Turley E, Wright J . Autocrine induction of tumor protease production and invasion by a metallothionein-regulated TGF-beta 1 (Ser223, 225). EMBO J. 1992; 11(4):1599-605. PMC: 556609. DOI: 10.1002/j.1460-2075.1992.tb05205.x. View